Press releases
- ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
- ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
- ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
- ChromaDex to Join Russell 2000® Index
- Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
- ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
- ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
More ▼
Key statistics
As of last trade Chromadex Corp (OCD1:STU) traded at 2.58, -34.85% below its 52-week high of 3.96, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.50 |
---|---|
High | 2.58 |
Low | 2.50 |
Bid | 2.70 |
Offer | 2.74 |
Previous close | 2.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 75.54m |
Free float | 48.51m |
P/E (TTM) | -- |
Market cap | 219.82m USD |
EPS (TTM) | -0.047 USD |
Data delayed at least 15 minutes, as of Jul 22 2024.
More ▼